The effect of a disease management algorithm and dedicated postacute coronary syndrome clinic on achievement of guideline compliance: results from the parkland acute coronary event treatment study

Journal of Investigative Medicine

Volumn 56, Issue 1, 2008, Pages 15-25

  Yorio, Jeff ^a   Viswanathan, Sundeep ^a,e   See, Raphael ^a   Uchal, Linda ^b   McWhorter, Jo Ann ^b   Spencer, Nali ^a   Murphy, Sabina ^c   Khera, Amit ^b,d   De Lemos, James A ^b,d   McGuire, Darren K ^b,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Donald W Reynolds Cardiovascular Clinical Research Center   (United States)

^e 5323 Harry Hines Blvd ^*  (United States)

Author keywords

Evidence based therapeutics; Physician extender; Post ACS care

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; METOPROLOL SUCCINATE; QUINAPRIL; RAMIPRIL; TICLOPIDINE; VALSARTAN; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALGORITHM; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIET; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; EXERCISE; FEMALE; FOLLOW UP; HEART REHABILITATION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MALE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PATIENT PARTICIPATION; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; REFUSAL TO PARTICIPATE; SECONDARY PREVENTION; SMOKING CESSATION; TREATMENT DURATION; ACUTE DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY CARE UNIT; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SYNDROME; TREATMENT OUTCOME;

ACUTE DISEASE; ALGORITHMS; CARDIOVASCULAR AGENTS; CORONARY CARE UNITS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SYNDROME; TREATMENT OUTCOME;

EID: 40949146490     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/jim.0b013e3181620295     Document Type: Article

References (33)

1. Heart Disease and Stroke Statistics-2006 Update. Dallas, TX: American Heart Association; 2006.
2. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed). 1988;296(6618):320-331.
3. Yusuf S, Sleight P, Held P, et al. Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. Circulation. 1990;82(3 suppl):IΠ 17-11134.
4. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280(7):623-629.
5. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90(4):2056-2069.
6. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. NEnglJMed. 1992;327(10):669-677.
7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
9. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323(16):1112-1119.
10. Smith SC Jr, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92(l):2-4.
11. Braunwald E, Antrnan EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36(3):970-1062.
12. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273(19): 1509-1514.
13. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83(9):1303-1307.
14. Miller M, Byington R, Hunninghake D, et al. Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. Arch Intern Med. 2000;160(3):343-347.
15. Giles WH, Anda RF, Jones DH, et al. Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities. JAMA. 1993;269(9):1133-1138.
16. Frolkis JP, Zyzanski SJ, Schwartz JM, et al. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPΠ) guidelines. Circulation. 1998;98(9):851-855.
17. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J. 1997;18(10):1569-1582.
18. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87(7):819-822.
19. New JP, Mason JM, Freemantle N, et al. Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. Diabetes Care. 2003;26(8):2250-2255.
20. Denver EA, Barnard M, Woolfson RG, et al. Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with type 2 diabetes. Diabetes Care. 2003;26(8):2256-2260.
21. Allen JK, Blumenthal RS, Margolis S, et al. Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial. Am Heart J. 2002;144(4):678-686.
22. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23(15):1177-1189.
23. Tang E, Wong CK, Wilkins G, et al. Use of evidence-based management for acute coronary syndrome. N Z Med J. 2005;118(1223):U1678.
24. Keough-Ryan TM, Kiberd BA, Dipchand CS, et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis. 2005;46(5):845-855.
25. Campbell NC, Ritchie LD, Thain J, et al. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. Heart. 1998;80(5):447-452.
26. Allison JJ, Kiefe CI, Weissman NW, et al. Relationship of hospital teaching status with quality of care and mortality for Medicare patients with acute MI. JAMA. 2000;284(10): 1256-1262.
27. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117(2):73-81.
28. Lavie CJ, Milani RV. Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients. Am J Cardiol. 1997;79(4):397-401.
29. Lavie CJ, Milani RV, Littman AB. Benefits of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol. 1993;22(3): 678-683.
30. Lavie CJ. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2003;10(6):429-437.
31. Winslow E, Bohannon N, Brunton SA, et al. Lifestyle modification: weight control, exercise, and smoking cessation. AmJMed. 1996;101(4A):25S-31S. [discussion 31S-33S].
32. Rao SV, Kaul P, Newby LK, et al. Poverty, process of care, and outcome in acute coronary syndromes. J Am Coll Cardiol. 2003;41(11):1948-1954.
33. Sonel AF, Good CB, Mulgund J, et al. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). Circulation. 2005;111(10):1225-1232.